|
Status |
Public on Jul 14, 2020 |
Title |
ChIP-Seq for FOXA2 in PC3 cell line with GSK treatment and VEH control |
Organism |
Homo sapiens |
Experiment type |
Genome binding/occupancy profiling by high throughput sequencing
|
Summary |
We show in prostate cancer cells that LSD1 co-localizes with FOXA1 and active enhancer markers, and that LSD1 inhibition globally disrupts FOXA1 chromatin binding.
|
|
|
Overall design |
ChIP-Seq of FOXA2 was performed in PC3 cells treated with vehicle or GSK2879552
|
Web link |
https://doi.org/10.1038/s41588-020-0681-7
|
|
|
Contributor(s) |
Gao S, Han D, Chen S, He HH, Cai C |
Citation(s) |
32868907 |
|
Submission date |
Apr 20, 2020 |
Last update date |
Oct 13, 2020 |
Contact name |
Changmeng Cai |
E-mail(s) |
changmeng.cai@umb.edu
|
Organization name |
University of Massachusetts Boston
|
Street address |
100 William T. Morrissey Blvd.
|
City |
Boston |
State/province |
Massachusetts |
ZIP/Postal code |
02125 |
Country |
USA |
|
|
Platforms (1) |
GPL16791 |
Illumina HiSeq 2500 (Homo sapiens) |
|
Samples (4)
|
|
This SubSeries is part of SuperSeries: |
GSE149007 |
Lineage-specific chromatin binding of FOXA1 is regulated by LSD1-mediated demethylation |
|
Relations |
BioProject |
PRJNA627123 |
SRA |
SRP257690 |